Generalized Anxiety Disorder – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of generalized anxiety disorder (GAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the prevalence of GAD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s GAD forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GAD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following patient populations:
- Total 12-month prevalent cases of GAD based on DSM-IV criteria.
- Total 12-month prevalent cases of GAD based on DSM-5 criteria.
- Total prevalent cases of GAD by severity based on DSM-IV and DSM-5 criteria.
- Total prevalent cases of GAD (DSM-5) by comorbidity.
Note: Coverage may vary by country.
Table of contents
- Generalized Anxiety Disorder - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of generalized anxiety disorder)
- Total 12-month prevalent cases of GAD based on DSM-IV criteria
- Total 12-month prevalent cases of GAD based on DSM-5 criteria
- Total prevalent cases of GAD by comorbidity based on DSM-5 criteria
- Total prevalent cases of GAD by severity based on DSM-IV and DSM-5 criteria
- Risk/protective factors applied to disease forecast models
- Reference Materials
